Perspective Complete Prescribing Details OPDIVO® (nivolumab) is indicated with the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or right after three or even more lines of systemic therapy that features auto